KRAS and pancreatic intraductal papillary-mucinous neoplasm: KRAS activation is observed in precursor lesions such as pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN), identifying it as a major genetic driver.11